<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01342120</url>
  </required_header>
  <id_info>
    <org_study_id>D1443L00085</org_study_id>
    <nct_id>NCT01342120</nct_id>
  </id_info>
  <brief_title>PHARMO Institute Seroquel Safety Study</brief_title>
  <acronym>PHARMO II</acronym>
  <official_title>Seroquel Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PHARMO Institute for Drug Outcomes Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to study specific outcomes of interest in users of
      quetiapine compared with all other atypical antipsychotics and specifically olanzapine and
      risperidone. The outcomes of interest are all-cause mortality, failed suicide attempts,
      extrapyramidal symptoms, diabetes mellitus, hypothyroidism, acute myocardial infarction and
      stroke. This retrospective cohort study is based on population-based record linkage system
      (PHARMO RLS) capturing about 2.5 millions residents in the Netherlands.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The outcomes of interest will be evaluated by means of relative risk based on incidence rates estimates in users of quetiapine vs corresponding incidence rates in users of comparison drugs</measure>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">18325</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Major Depressive Disorder</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Quetiapine</arm_group_label>
    <description>Quetipine users</description>
  </arm_group>
  <arm_group>
    <arm_group_label>All other atypical antipsychotics</arm_group_label>
    <description>All other atypical antipsychotics users</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone</arm_group_label>
    <description>Risperidone users</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <description>Olanzapine users</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Population based sample of about 2.5 millions residents in the Netherlands
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Episode of new use of atypical antipsychotics in na√Øve (not used antipsychotic drugs
             for a year) users of antipsychotics.

        Exclusion Criteria:

          -  less than a year of recorded history before the cohort entry date

          -  use of multiple antipsychotics concomitantly

          -  duration and dose of the antipsychotic drug cannot be determined
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edith Heintjes</last_name>
    <role>Principal Investigator</role>
    <affiliation>PHARMO Institute for Drug Outcomes Research</affiliation>
  </overall_official>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>April 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2011</study_first_posted>
  <last_update_submitted>August 31, 2011</last_update_submitted>
  <last_update_submitted_qc>August 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atypical antipsychotics</keyword>
  <keyword>quetiapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

